Pancreatic Cancer Research

ResearcherFred and Pamela Buffett Cancer CenterActive in the last 2 years

Jean L. Grem

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1672-9416; OpenAlex author ID A5045440420. Sources: OpenAlex.

Their work

Papers
14 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
104
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 3 papers · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 14

  1. The circadian gene Dec2 promotes pancreatic cancer progression and dormancy through immune evasion. Co-author DOI 10.1016/j.devcel.2026.04.001↗
  2. Distinct glycosyltransferase expression governs organ-specific survival in pancreatic cancer metastasis. Co-author DOI 10.1038/s41388-026-03896-5↗
  3. Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer. Co-author DOI 10.1038/s41586-025-08927-x↗
  4. Engrailed-1 Promotes Pancreatic Cancer Metastasis. Co-author DOI 10.1002/advs.202308537↗
  5. Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling. Co-author DOI 10.1016/j.ebiom.2021.103772↗
  6. Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-020-01518-2↗
  7. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response. Co-author DOI 10.1158/1078-0432.ccr-19-1496↗
  8. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma. Last author DOI 10.1016/j.radonc.2018.11.002↗
  9. Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic A… Last author DOI 10.1097/coc.0000000000000599↗
  10. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-18-0349↗
  11. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.06.004↗
  12. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Co-author DOI 10.1016/j.cell.2017.07.007↗
  13. De Novo Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-16-3062↗
  14. Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer. Co-author DOI 10.1111/bcp.12620↗

Closest collaborators

The 25 strongest of 104 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Anthony Hollingsworth · 9 shared papers, 2017–2026 · strength 1.12
  2. Paul M. Grandgenett · 8 shared papers, 2017–2026 · strength 1.04
  3. Surinder K. Batra · 3 shared papers, 2021–2026 · strength 0.43
  4. Moorthy Palanimuthu Ponnusamy · 3 shared papers, 2021–2026 · strength 0.43
  5. Hervé Tiriac · 3 shared papers, 2017–2025 · strength 0.38
  6. Thomas C. Caffrey · 3 shared papers, 2020–2025 · strength 0.36
  7. Geoffrey A. Talmon · 2 shared papers, 2022–2026 · strength 0.33
  8. Frank Leon · 2 shared papers, 2021–2026 · strength 0.32
  9. Palanisamy Nallasamy · 2 shared papers, 2021–2026 · strength 0.32
  10. Sanchita Rauth · 2 shared papers, 2021–2026 · strength 0.32
  11. Saravanakumar Marimuthu · 2 shared papers, 2021–2026 · strength 0.32
  12. Kavita B. Mallya · 2 shared papers, 2021–2026 · strength 0.32
  13. Lyudmyla Derby Berim · 4 shared papers, 2017–2022 · strength 0.30
  14. Chi H. Lin · 3 shared papers, 2019–2022 · strength 0.28
  15. Venkatesh Varadharaj · 1 shared paper, 2026 · strength 0.22
  16. Nivedeta Krishna Kumar · 1 shared paper, 2026 · strength 0.22
  17. Kirtana Arikath BS · 1 shared paper, 2026 · strength 0.22
  18. Jesse L. Cox · 1 shared paper, 2026 · strength 0.22
  19. Zahraa Wajih Alsafwani · 1 shared paper, 2026 · strength 0.22
  20. Christopher R. Vakoc · 2 shared papers, 2017–2024 · strength 0.21
  21. Jae‐Seok Roe · 2 shared papers, 2017–2024 · strength 0.21
  22. Chang‐Il Hwang · 2 shared papers, 2017–2024 · strength 0.21
  23. Youngkyu Park · 2 shared papers, 2017–2024 · strength 0.21
  24. David Arthur Tuveson · 2 shared papers, 2017–2024 · strength 0.21
  25. Rama Krishna Nimmakayala · 2 shared papers, 2021–2022 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.